Marketing-Börse PLUS - Fachbeiträge zu Marketing und Digitalisierung
print logo

Osteoporosis Drugs Market Size, Analysis and Growth, 2022

Global osteoporosis drugs market was valued at $8,835.4 million in 2015 and it is expected to grow at a CAGR of 3.8% till 2022.
vijay mishra | 16.11.2017
©
The global osteoporosis drugs market is growing at a significant rate due to growing geriatric population, increasing awareness of osteoporosis and increasing healthcare expenditure. The increasing prevalence of osteoporosis in postmenopausal women and the increasing focus on research & development of new drugs for treatment of osteoporosis are also driving the growth of the global osteoporosis drugs market.

Explore Detailed Description of the Report at: https://www.psmarketresearch.com/market-analysis/osteoporosis-drugs-market

Some of the signs and symptoms of the osteoporosis are falling risk and fractures. Diagnostic tests of osteoporosis include X-Ray test and traditional radiography tests, which is further confirmed by bone density test. Osteoporosis disease can be managed by nutrition emphasis, lifestyle management and medicines. The factors such as strict regulatory requirement for the approval of osteoporosis drugs, patent expiry of blockbuster drugs, and side-effects and complications associated with osteoporosis drugs are inhibiting the growth of the global market.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/osteoporosis-drugs-market/report-sample

Some of the key companies operating in the global osteoporosis drugs market include Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche, Novartis International AG, Merck & Co. Inc. and Amgen Inc.